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Interaction Between Sodium Intake,
Angiotensin II, and Blood Pressure
as a Cause of Cardiac Hypertrophy
Trefor Morgan, Jean-Francois Aubert, and Hans Brunner
Cardiac hypertrophy is common in hypertension but its
development is influenced by angiotensin II, sodium in-
take aldosterone, and the time of day blood pressure (BP)
is elevated. This study examined and compared cardiac
hypertrophy in the 2 kidney-1 clip (2K-1C) and 1 kidney-1
clip (1K-1C) Goldblatt models of hypertension. Blood
pressure was measured by telemetry in a selected group of
rats. Rats were placed on a high (4%) or reduced (0.2%)
salt intake and were given captopril (75 mg/kg per day) or
losartan (10 mg/kg per day). Appropriate sham-operated
and untreated controls were used.
Cardiac hypertrophy was greater in the 1K-1C than in
the 2K-1C model. Day and sleep BP were also higher. In
the 2K-1C model BP was lower on the reduced salt intake
and BP decreased with captopril in both reduced and high
salt groups. Cardiac weight and index decreased signifi-
cantly only in the reduced salt and captopril group and was
less than the size before treatment. In the 1K-1C model
captopril caused all BP measures to decrease in the re-
duced salt group but had no significant effect in the high
salt group. Cardiac weight and index were reduced only in
the reduced salt 1 captopril group and cardiac weight was
less than the pretreatment control. Losartan had a similar
effect in the 1K-1C model to that achieved with captopril.
The responses achieved correlated in part with renin status
and dependency level.
There is no prime determinant of cardiac hypertrophy.
Blood pressure, sodium intake, and hormonal status are
all important. It is postulated that the common pathway
may be alterations in cell composition that signal the
nucleus to increase cell growth. Am J Hypertens 2001;
14:914–920 © 2001 American Journal of Hypertension,
Ltd.
Key Words: Angiotensin II, cardiac hypertrophy,
hypertension, Goldblatt hypertension, angiotensin con-
verting enzyme inhibitors, AT1 receptor blockers.
C ardiac hypertrophy is an independent predictor ofcardiac morbidity and mortality and is commonlypresent in people and animals with high blood
pressure.1,2 However, it is unclear what factors are the
major contributors to this cardiac enlargement. High blood
pressure (BP) by increasing cardiac wall stress or by
increased cardiac work undoubtedly contributes to its de-
velopment.3–5 However, other factors are clearly of im-
portance.6 Angiotensin II elevates BP but also has direct
effects on cardiocytes in vivo and in culture, increasing the
production of various mRNAs, which could be the cause
of cardiac enlargement. But if BP elevation was prevented
in rats, cardiac hypertrophy did not result.7 These results
were not reproduced by other investigators8 who claim
that angiotensin II can cause left ventricular hypertrophy
(LVH) independent of BP elevation. In volume load hy-
pertrophy, which causes both right and left ventricular
enlargement, blockade of the renin system either by an-
giotensin converting enzyme (ACE) inhibitors or by AT1
receptor blocking drugs causes resolution of the enlarge-
ment of both ventricles.9,10 Another factor causing LVH is
increased sodium chloride intake.11 Rats given extra NaCl
develop cardiac hypertrophy with no obvious increase in
BP. However, it is possible that BP may have been ele-
vated at night because it was not assessed by telemetry. In
these salt-loaded models renin and angiotensin II levels
would be low, suggesting that there may be an interaction
between NaCl intake and angiotensin II at the cellular
level. A low NaCl intake reduces the hypertrophy caused
by angiotensin II, whereas a high NaCl intake appears to
augment the hypertrophy response with little effect on
BP.12,13 Aldosterone has also been reported to cause LVH,
but its interaction with sodium intake and angiotensin II
levels has not been fully studied.14
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A number of factors may cause resolution of LVH.
Thus, it has been reported that bradykinin accumulation in
the heart caused by low-dose ACE inhibitors may allow
resolution of LVH without an effect on BP.15 It has also
been suggested that angiotensin II acting through the an-
giotensin type II receptor may prevent the usual pressor
and chronotrophic effects of angiotensin II.16
This study was set up to observe the interactions be-
tween BP (assessed by telemetry), sodium intake, and
inhibition of converting enzyme or blockade of the AT1
receptor in two rat models of Goldblatt hypertension.
Blood pressure in the 2 kidney-1 clip (2K-1C) model is
initially a renin-dependent model and it has been stated
that the renin dependency diminishes with time. The 1
kidney-1 clip (1K-1C) model of hypertension can be either
renin dependent or renin independent according to the
sodium intake.
Methods
The experiments were performed on Wistar rats ob-
tained from IFFA-Credo, Domaine des Oncins, 69210
L’Arbresle, France.
Blood Pressure Assessment
Blood pressure was measured continuously by telemetry
in a number of rats (Griffiths C, Morgan TO, Delbridge
LMD, unpublished data).17 In general, one telemetry rat
was used as a surrogate for four experimental rats and the
animals were treated in an identical fashion except that a
telemeter was inserted into the abdominal aorta 2 weeks
before hypertension was created (concurrent study). To
obtain confirmatory data related to the effect of diet and
drugs on BP, a supplementary procedure was undertaken
at the end of the study. The groups of rats with telemeters
in place were randomly assigned to receive each of the
therapeutic procedures for a 1-week period. The data from
day 4 to day 7 of each intervention was used to assess the
response to that therapy (crossover study). While the tele-
meters were in place, BP was sampled over a 10-sec
interval every 10 min and the BP was accumulated and
assessed using the Dataquest system (Data Science Inter-
national, St Paul, MN).
Cardiac Hypertrophy and
BP in the Experimental Rat Group
Twenty-four hours before the end of the study rats were
anesthetized with fluothane and a cannula was inserted
into the femoral artery and exteriorized at the back of the
head. The rats were allowed to recover and the next day
BP was recorded in a conscious rat during a 1-h interval.
Rats in the experimental group that had a mean arterial
pressure ,130 mm Hg were excluded from the study.
Captopril was not administered after the cannula was
inserted and thus the BP recording was made approxi-
mately 36 to 40 h after the last dose of captopril. Obser-
vations in rats with telemeters indicated that BP had re-
turned to untreated levels by this time. After BP was
measured rats were killed and the heart removed. The
great vessels and the atria were removed and the heart was
blotted dry and weighed. The weight was recorded in
milligrams but was also factored by the body weight of the
rat to give a cardiac index.
Renin Status and
Angiotensin Dependency
Plasma renin concentration was measured on a sample of
blood collected by orbital puncture under light ether an-
esthetic 2, 4, and 8 weeks after a clip was placed on the
renal artery. The renin concentration was determined by
adding 24-h nephrectomized rat plasma and the angioten-
sin I generated was measured by radioimmunoassay. The
responsiveness of the BP was determined by giving an
intraperitoneal injection of captopril (10 mg/kg) to the rats
with telemeters inserted. The BP was sampled during a
10-sec interval every 5 min for the next 2 h and the peak
decrease in BP determined. This procedure was done in
rats 2, 4, and 8 weeks after the Goldblatt hypertension was
created.
Model 1: 2K-1C Goldblatt Hypertension
Wistar rats weighing approximately 300 g were anesthe-
tized and a 0.20-mm silver clip was placed around the left
renal artery. The rats were allowed to recover and were
placed on their normal diet for 3 weeks. A group of rats
had a sham operation performed. At 3 weeks a group of
the sham-operated and 2K-1C rats were killed and cardiac
size assessed as stated above. Sham-operated rats were
divided into two groups and placed on a reduced (0.2%) or
high (4%) NaCl diet. The 2K-1C rats were divided into
two groups and placed on the high or reduced salt intake.
The 2K-1C rats were further divided into two groups and
one group on the high or reduced salt intake was given
captopril in the drinking water with the concentration
adjusted to give an intake of 75 mg/kg per day. When rats
were allocated to groups this was done in a stratified
manner to provide groups of approximate equal weights.
Rats were treated for 4 weeks and at the end of that time
were killed and cardiac size measured.
Model 2a: 1K-1C Goldblatt Hypertension
Wistar rats of approximately 275 g had their right kidney
removed and a 0.20-mm silver clip placed around their left
renal artery. They were allowed to recover. Groups of rats
were treated in a similar manner to the 2K-1C model. At
the end of the study the rats were treated as stated above.
Model 2b: 1K-1C
This group was similar to model 2a with the following
difference. In this model there were no sham-operated or
untreated controls. Three weeks after hypertension was
created rats were placed on a high or reduced NaCl intake
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and given losartan (10 mg/kg per day) intraperitoneally at
08:00 daily for 4 weeks. The two groups were then studied
as stated above.
Statistical Analysis
The results are presented with the mean and SEM. The
comparison in the crossover study of the response in BP
was made by ANOVA and by paired t tests with Bon-
ferroni correction. The other data was analyzed by one- or
two-way ANOVA as appropriate. For each ANOVA a




Telemetry BP Telemetry was not performed on the
sham-operated rats in this study and values for sham-
operated rats on a normal diet are from a previous study in
rats of the same strain and size17 (24 h, 115 6 3 mm Hg;
awake, 131 6 5 mm Hg; sleep, 108 6 3 mm Hg). At the
end of the 3-week period BP was elevated in all eight rats
in which a clip had been placed around the left renal artery
(Table 1). The results in the concordant study and the
crossover study were similar. Only results from the cross-
over study are shown (Table 1). Systolic BP was highest in
the 2K-1C Goldblatt rats on a high salt (4%) intake. This
was the situation for 24 h, awake, and sleep BP. In rats on
a high and reduced salt intake captopril (75 mg/day)
caused a significant decrease in all pressures measured.
The lowest BP was achieved with reduced salt and capto-
pril (Table 1). The decrease in 24-h BP when captopril was
given to rats on a reduced salt diet was greater than when
captopril was given to rats on a high salt intake (30 6 4
mm Hg v 22 6 3 mm Hg, P 5 .01).
Plasma Renin and Angiotensin Dependency of BP A
group of untreated 2K-1C Goldblatt rats with BP teleme-
ters inserted were followed for 8 weeks on a 0.2% and 4%
NaCl intake. The acute response to an intraperitoneal
injection of captopril (10 mg/kg) was measured. Rats on
0.2% NaCl intake had a lower systolic BP than rats on 4%
NaCl intake (Table 2). The decrease in BP on the two diets
did not differ but the systolic BP at time of peak response
to captopril was lower in the rats on 0.2% NaCl (147 6 3
mm Hg v 173 6 5 mm Hg, P , .001). There was no
difference in response with time. Plasma renin concentra-
tion was higher on the 0.2% NaCl intake and on both 0.2%
and 4% NaCl dietary intakes it tended to decline with time
(Table 2).
Cardiac Size At week 3 sham-operated rats were di-
vided into three groups. One group was killed and the
other two placed on a high or reduced salt intake, respec-
tively, for 4 weeks. The rats grew to a similar extent
(Table 3). Cardiac weight and cardiac index tended to be
greater in the rats on a high salt intake but changes were of
marginal significance. At week 3, 40 2K-1C Goldblatt rats
were divided into five groups. One group was killed and
the other four groups treated as indicated (Table 3). The
reduced salt 1 captopril group did not grow as well as the
other groups (P , .05). When BP was measured in the
experimental rats by an intra-arterial cannula at the end of
the experiment five rats did not meet our criteria for
hypertension and were excluded from analysis (Table 3).
In rats on a reduced salt diet 1 captopril, cardiac size and
index were lower than in all other treatment groups and
were less than in the untreated group at week 3 indicating
cardiac involution (Table 3). The values were not different
from sham-operated controls. In rats on a high salt intake
and captopril there was a small reduction in heart weight
and cardiac index compared to the untreated 2K-1C rats on
a high salt intake (P , .05). In rats with 2K-1C Goldblatt
Table 1. Chronic response of systolic blood pressure (mm Hg) to captopril (75 mg/kg/day) in rats on a high
(4%) and reduced (0.2%) sodium chloride intake
Untreated
(Week 3)
High Salt 4% Reduced Salt 0.2%
Control Captopril Control Captopril
2K-1C
n 8 7 7 7 6
24 h 176 188 166 162 132*
Awake 20:00–24:00 188 196 175 175 146*
Sleep 08:00–12:00 152 172 151 143 110*
1K-1C
n 8 6 6 6 6
24 h 202 203 190 186 136*
Awake 20:00–24:00 214 212 200 204 144*
Sleep 08:00–12:00 195 192 179 158* 113*
SEM were between 4 and 8 for all measurements.
For all blood pressure measurements in the 2K-1C model; high salt . high salt 1 Capt 5 reduced salt . reduced salt 1 Capt, P , .09 by
ANOVA and paired t test with Bonferroni correction.
* P , .001 compared with all values to the left by ANOVA and paired t test with Bonferroni correction.
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hypertension on a high salt intake cardiac index and car-
diac weight were higher than in the sham-operated or
reduced salt–captopril-treated 2K-1C group. There was a
trend for cardiac weight to be higher in this high salt group
compared to rats on a high salt diet 1 captopril (P , .05)
and those on a reduced salt diet (P 5 .08) (Table 3).
1K-1C Goldblatt Model
Telemetry BP Blood pressure was elevated in all rats at
week 3. Two of the telemetry rats died during the study.
Both were on a high salt intake, one on captopril and one
on no drugs. The only group that had a large decrease in
BP were the rats on a reduced salt intake that received
captopril and the BP in these rats decreased toward the
normal level. In the crossover study performed in the six
remaining rats similar results were observed with the BP
having the following order (lowest first), reduced salt 1
captopril, reduced salt, high salt 1 captopril, high salt.
Captopril had only a minor effect on BP in the rats on a
high salt intake (12 6 4 mm Hg), but had an extremely




Systolic Blood Pressure (mm Hg)
Initial Fall Lowest BP
2K-1C 0.2% NaCl
2 weeks 6.4 6 1.2 172 6 6 32 6 4 140 6 5
4 weeks 6.8 6 1.1 178 6 5 31 6 5 147 6 5
8 weeks 3.9 6 1.1 187 6 7 34 6 3 153 6 4
2K-1C 4% NaCl
2 weeks 1.4 6 0.8 193 6 7 23 6 4 170 6 6
4 weeks 1.2 6 0.6 198 6 6 25 6 4 173 6 4
8 weeks 1.0 6 0.3 202 6 9 28 6 3 174 6 7
1K-1C 0.2% NaCl
2 weeks 4.4 6 0.5 189 6 7 56 6 5 133 6 5
4 weeks 4.1 6 0.5 196 6 8 52 6 4 144 6 6
8 weeks 4.9 6 0.4 207 6 6 61 6 6 146 6 4
1K-1C 4% NaCl
2 weeks 0.4 6 0.2 195 6 6 12 6 3 183 6 5
4 weeks 0.5 6 0.2 203 6 4 8 6 2 195 6 5
8 weeks 0.4 6 0.2 216 6 6 11 6 3 205 6 6
BP 5 blood pressure.
Mean; SEM; n 5 4.









Sham operated (wk 3) 8 357 6 6 771 6 15 2.16 6 0.05
High salt (wk 7) 8 401 6 6 890 6 22 2.22 6 0.06
Reduced salt (wk 7) 8 399 6 7 806 6 18 2.02 6 0.06
Experimental (wk 3) 8 354 6 5 948 6 24 2.78 6 0.05
High salt (wk 7) 7* 381 6 7 1120 6 25 2.94 6 0.06
High salt 1 Capt (wk 7) 7* 392 6 6 1027 6 24 2.62 6 0.06
Reduced salt (wk 7) 6* 396 6 7 1077 6 21 2.72 6 0.06
Reduced salt 1 Capt (wk 7) 7* 365 6 5 781 6 23‡ 2.14 6 0.06‡
1K-1C
Sham operated (wk 3) 8 334 6 6 731 6 21 2.19 6 0.05
(wk 7) 8 373 6 6 788 6 23 2.14 6 0.06
Experimental (wk 3) 8 287 6 6 1028 6 28 3.58 6 0.08
High salt (wk 7) 4† 325 6 12 1311 6 24 4.03 6 0.09
High salt 1 Capt (wk 7) 7† 335 6 9 1237 6 35 3.69 6 0.13
Reduced salt (wk 7) 9 305 6 9 1244 6 17 4.08 6 0.06
Reduced salt 1 Capt (wk 7) 9 289 6 5 826 6 15§ 2.86 6 0.05§
Capt 5 captopril.
* These groups were 8 rats at allocation but 5 rats were excluded because they did not meet the hypertension criteria.
† 5 and 2 rats died in each of these groups and were smaller than those that survived.
‡ P , .01 compared to all other values in 2K-1C model and not different from sham-operated controls.
§ P , .05 compared to all other values in 1K-1C model but significantly higher than controls.
Statistical comparison with two-way analysis of variance with post hoc SNK correction.
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large effect on BP in rats on the reduced salt intake (50 6
6 mm Hg).
Plasma Renin and Angiotensin Dependency of BP A
group of untreated 1K-1C Goldblatt rats with telemeters
inserted were followed for 8 weeks on a 0.2% and 4%
NaCl intake. One rat on the high salt intake died at week
5. The acute response to an intraperitoneal injection of
captopril (10 mg/kg) was measured (Table 2). There was
no significant difference in BP on the 0.2% and 4% NaCl
intake, but the decrease in BP with captopril was signifi-
cantly greater (P , .001) in rats on 0.2% NaCl. The
systolic BP at time of peak response in the rats on 0.2%
NaCl (142 6 4 mm Hg) was significantly lower (P ,
.001) than the BP in rats on 4% NaCl (204 6 11 mm Hg).
Plasma renin concentration in rats on 4% NaCl was very
low and increased significantly on 0.2% NaCl (Table 2).
Cardiac Size By week 3, five rats that had a 1K-1C
procedure had died and the remaining 44 rats were ran-
domized to five groups matched for body weight. One
group of eight rats were killed and the other four groups of
nine animals were placed on their appropriate treatments
(Table 3). During the 4 weeks of treatment seven rats died.
Five were in the high salt group and two in the high salt 1
captopril group. All surviving rats met the criteria for
hypertension assessed by intraarterial cannulation and
were included in the analysis (Table 3). The rats with
1K-1C hypertension did not grow as rapidly as the sham-
operated controls. The rats on the reduced salt intake did
not grow as well as those on the high salt intake, but it is
difficult to be certain of the importance of this difference as
the rats that died in the high salt group were smaller than
the others.
Cardiac weight and cardiac index were greater at week
7 compared to the value at week 3 in the reduced salt, high
salt, and high salt 1 captopril group (P , .01). In the rats
on a high salt intake given captopril there was a possible
decrease in cardiac index and cardiac weight compared to
the rats on a high salt intake. However, the high mortality
in these groups makes comparison hazardous. In the group
on a reduced salt intake 1 captopril the cardiac weight and
cardiac index were lower than in the other three groups
and were less than the values in the untreated group at




Four rats had telemeters inserted. The BP during the
concordant study and in the crossover study at the end of
the experimental study was lower in the reduced salt rats
given losartan (Table 4). In the rats on a high salt intake 1
losartan the BP did not differ from the BP on a high salt
intake in the previous study. Cardiac weight and cardiac
index were lower in the rats on a reduced salt intake and
losartan (Table 4). In rats on a high salt intake and losar-
tan, cardiac weight and index was not different from
untreated rats of the same age in the previous study.
Comparison Between the Two Models
In the untreated rats, 3 weeks after the surgical model was
created, heart weight and heart index were greater in the
1K-1C model than in the 2K-1C model (P , .01). In the
1K-1C model there appeared to be a continuation of the
increase in cardiac size as heart weight and cardiac index
both increased. In the 2K-1C model it appeared that the
hypertrophy was fully expressed by week 3 as there was
no further increase in cardiac size.
Discussion
The BP levels in the two Goldblatt models were similar
but cardiac hypertrophy in the 1K-1C model was greater
than in the 2K-1C model. The second model is stated to be
the angiotensin-dependent model and therefore, this dif-







24-h BP* 198 6 10 152 6 7 ,.001
Awake BP (20:00–24:00) 190 6 12 121 6 12 ,.001
Sleep BP (08:00–12:00) 208 6 15 168 6 12 ,.001
n 8 8
Died 1 0
Body weight (g) 345 6 8 325 6 6
Heart weight (mg) 1415 6 49 884 6 36 ,.01
Cardiac index (mg/g) 4.10 6 0.13 2.72 6 0.08 ,.01
Abbreviation as in Table 2.
* BP levels are those during the crossover study.
P values with Bonferroni correction.
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ference is surprising and suggests that a factor present in
the 1K-1C model is more important than angiotensin II.
The 24-h mean BP, and in particular sleep BP, was higher
in the 1K-1C model and this might contribute to the
different degree of hypertrophy. Both models show circa-
dian variation in BP and the difference between sleep and
awake BP was greater in the 2K-1C model (36 mm Hg)
than in the 1K-1C model (19 mm Hg), leading to a higher
sleep BP in this later model. From previous studies,17,18 it
has been inferred that sleep BP is a more important deter-
minant of LVH than other BP indices. Although there
were differences in sleep BP, other explanations are pos-
sible.
In the 2K-1C model, blockade of the angiotensin sys-
tem with ACE inhibitors caused a decrease in BP inde-
pendent of the NaCl intake, although the final pressure
achieved was lower in the rats on the reduced salt intake as
well as captopril. The effect of reduced salt diet and ACE
inhibition was at least additive. Cardiac size in the reduced
salt 1 captopril group returned to a similar value as in
sham-operated rats. In rats on a high salt intake 1 capto-
pril there was a small decrease in cardiac weight but the
cardiac weight and cardiac index were greater than in
sham-operated controls and in the reduced salt and capto-
pril group.
The 1K-1C model is often stated to be a volume-
dependent model, or more correctly a sodium-retaining
model, which leads to development of hypertension. How-
ever, there are clearly interactions between sodium reten-
tion and angiotensin II in the development and perpetua-
tion of hypertension. In the 1K-1C model a significant
reduction in BP toward the normal level was only obtained
in rats on a reduced salt diet in which the action of
angiotensin II was prevented. This reduction in BP oc-
curred whether the system was blocked by ACE inhibitors
or by an AT1 receptor-blocking drug. Associated with the
decrease in BP there was resolution of cardiac hypertro-
phy. Blood pressure and LVH were reduced in parallel,
suggesting that the BP signal was of major importance
(Fig. 1).
The dose of captopril or losartan used would be ex-
pected to prevent the effect of angiotensin II throughout
the 24-h period. Despite this blockade cardiac hypertrophy
persisted and therefore, it would appear that angiotensin II
is not essential to allow persistence of cardiac hypertro-
phy. It is possible that AT1 receptors are upregulated on a
high salt intake or alternatively that despite blockade of
plasma ACE there is still tissue conversion immediately
adjacent to the AT1 receptor and thus, blockade is not
complete. However, in normotensive rats (Griffiths C,
Morgan TO, Delbridge LMD, unpublished data), com-
bined ACE inhibition and AT1 blockade causes regression
of cardiac size. This regression is prevented by a high salt
intake, although BP still decreases, but not to the same
extent. This suggests that angiotensin II may be important
to maintain normal cardiac size and cause cardiocyte
growth, but the effect of absence of angiotensin II can be
prevented by a high salt intake.
Bradykinin has been implicated as an important factor
that can cause resolution of cardiac hypertrophy.15 The
present data are contradictory to the hypothesis that bra-
dykinin is of critical importance because with high dose
captopril on a high salt intake there was no resolution of
LVH and bradykinin levels would have been expected to
be elevated. It must be emphasized that these results do not
mean that bradykinin may not contribute in certain cir-
cumstances to resolution or prevention of LVH, but it is
not of critical importance.
From this and our previous studies (Griffiths C, Morgan
TO, Delbridge LMD, unpublished data),12,13,17 the follow-
ing conclusions can be drawn. Elevated BP probably
working by way of wall stress or by an acute increase in
cardiac work is important to initiate the signal that leads to
LVH. However, similar levels of BP may have different
results dependent on the time of day. An elevated BP
during the sleep (and possibly the awakening) period
appears to more clearly cause LVH. If BP is normalized
for 24 h or even during the sleep period, cardiac hyper-
trophy resolves. In no situation did we obtain significant
reduction in cardiac hypertrophy unless BP was normal-
ized either completely or during the sleep period. The role
of angiotensin II is complex. In rats on a reduced salt
intake it appears to be essential to maintain normal car-
diocyte and possibly somatic growth. However, this re-
quirement is overcome if rats are on a high salt intake.
When on a high salt intake the prevention of angiotensin II
effect by ACE inhibition or by AT1 receptor blockade or
by their combination (Griffiths C, Morgan TO, Delbridge
LMD, unpublished data) has little or no effect on cardiac
size.
FIG. 1. Correlation between the mean 24-h blood pressure as-
sessed by telemetry and the weight of the heart in the 2K-1C and
the 1K-1C model in different diet and therapeutic regimes. Despite
markedly different hormonal environments (eg, high bradykinin,
low plasma angiotensin II, unopposed AT2 action) there was a
strong correlation between 24-h blood pressure and cardiac weight.
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There has been a recent tendency to regard angiotensin
II as being all important related to BP and its inherent
complications, but the initial work relating morbidity to
renin levels clearly emphasized the importance of sodium
in this relationship.19 The exact mechanism that controls
these changes is not clearly determined but may relate to
effects that angiotensin II and sodium balance have on the
ionic composition of different cells.20–22 Thus, angiotensin
II and high sodium intake may both alter cellular electro-
lyte composition in a similar way but by different mech-
anisms and thus additive adverse consequences may result.
Likewise, prevention of the adverse effects of angiotensin
II may not result from its blockade if a person or animal is
on a high salt intake. Similarly, adverse effects of angio-
tensin II may not occur on a reduced salt intake because
the critical changes in cellular electrolyte concentration
may not result. The exact electrolyte changes of impor-
tance are not clear and are probably multifactorial.21,22
However, this study reinforces the importance of the in-
teraction of BP, sodium, and angiotensin II in determining
the final response.
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